Aclaris Therapeutics, Inc. - Common Stock (ACRS)
Frequently Asked Questions About Aclaris Therapeutics, Inc. - Common Stock (ACRS)
Does Aclaris Therapeutics have any partnerships or collaborations?
Yes, Aclaris Therapeutics engages in strategic partnerships and collaborations with other biopharmaceutical companies, academic institutions, and research organizations. These collaborations aim to leverage combined expertise, share resources, and accelerate the development of innovative therapies to serve dermatological patients more effectively.
How can investors stay updated on Aclaris Therapeutics?
Investors can stay updated on Aclaris Therapeutics by following the company's official website for press releases, access to financial reports, and updates on clinical trials. Additionally, subscribing to their mailing list or following their official social media channels can provide timely information regarding the company's activities and stock performance.
How does Aclaris Therapeutics prioritize patient needs?
Aclaris Therapeutics prioritizes patient needs by focusing on diseases with high unmet medical need. The company engages with patient communities and healthcare providers to understand the challenges faced by individuals with dermatological conditions, ensuring that its development efforts align with patient priorities and expectations.
How does Aclaris Therapeutics utilize innovation?
Aclaris Therapeutics embraces innovation by leveraging cutting-edge scientific research and advanced drug development techniques. The company focuses on harnessing next-generation dermatological treatments and novel mechanisms of action to create solutions that meaningfully improve patient outcomes in dermatological care.
How is Aclaris Therapeutics funded?
Aclaris Therapeutics, Inc. is funded through a combination of public equity offerings, partnerships, and investment by institutional investors. This funding allows the company to support ongoing clinical trials, research and development efforts, and operational expenses associated with its therapeutic pipeline.
On which stock exchange is Aclaris Therapeutics listed?
Aclaris Therapeutics, Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol ACRS. Being listed on Nasdaq allows the company to access capital markets and invest in the development of its innovative therapies.
What are some other product candidates in Aclaris' pipeline?
In addition to ATX-101, Aclaris has several other product candidates in its pipeline targeting a range of dermatological conditions. This includes AK-001 for the treatment of atopic dermatitis and AK-002 for the treatment of acne vulgaris, among others, showcasing the company's commitment to broadening its therapeutic offerings.
What are the company's future plans?
Aclaris Therapeutics has plans to expand its pipeline by advancing its existing product candidates through clinical trials and exploring new therapeutic targets. The company is committed to continuous innovation and aims to bring forth effective treatments for additional dermatological conditions in the future.
What challenges does Aclaris Therapeutics face?
Aclaris Therapeutics, like many biopharmaceutical companies, faces challenges such as the high costs and risks associated with drug development, navigating regulatory requirements, and ensuring commercial viability once products are approved. Additionally, the competitive landscape of dermatology necessitates ongoing innovation and strategic positioning.
What clinical trials is Aclaris Therapeutics currently conducting?
Aclaris Therapeutics is currently conducting several clinical trials evaluating the safety and efficacy of its product candidates, including ATX-101 and others. The specifics of these clinical trials can be accessed through clinical trial registries and the company's announcements, providing insights into their progress and results.
What does Aclaris Therapeutics, Inc. do?
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on the development of innovative drug therapies for skin diseases and conditions. Their primary focus lies in discovering, developing, and commercializing treatments for dermatological disorders, including alopecia areata, atopic dermatitis, and other inflammatory skin diseases.
What is Aclaris Therapeutics' approach to clinical trials?
Aclaris Therapeutics employs a rigorous and systematic approach to clinical trials, adhering to industry standards and regulatory requirements. The company designs its trials to assess the safety and efficacy of its product candidates, including phase 1, 2, and 3 studies, and actively engages with regulatory bodies throughout the process.
What is Aclaris Therapeutics' commitment to sustainability?
Aclaris Therapeutics is committed to sustainability by implementing practices that promote environmental responsibility, ethical business conduct, and community engagement. The company aims to minimize its environmental footprint while ensuring that its corporate governance aligns with sustainable development goals.
What is Aclaris Therapeutics' lead product candidate?
Aclaris Therapeutics' lead product candidate is ATX-101, a novel treatment for alopecia areata. This therapy aims to restore hair growth in patients with this autoimmune condition, marking an important step in addressing the unmet medical needs of individuals affected by hair loss.
What is the primary target market for Aclaris Therapeutics?
Aclaris Therapeutics primarily targets the dermatology market, which includes a variety of skin disorders such as alopecia areata and atopic dermatitis. The company aims to address significant unmet needs within this market by developing effective therapies for patients.
What is the significance of Aclaris Therapeutics' name?
The name Aclaris is derived from a combination of the term 'a' which signifies 'advanced' and the Latin word 'claris' meaning 'clear.' This reflects the company's mission to provide clear, effective, and advanced solutions for skin health challenges, emphasizing its dedication to innovation within dermatology.
When was Aclaris Therapeutics founded?
Aclaris Therapeutics, Inc. was founded in 2012. Since its establishment, the company has been dedicated to advancing dermatological research and bringing new, effective treatments to market for patients suffering from various skin conditions.
Where is Aclaris Therapeutics headquartered?
Aclaris Therapeutics, Inc. is headquartered in Wayne, Pennsylvania, USA. This location serves as the central hub for its research, clinical development, and corporate activities as the company continues to grow and develop new therapeutic options.
Who are the key executives at Aclaris Therapeutics?
The leadership team at Aclaris Therapeutics includes experienced professionals from the biopharmaceutical industry. Key executives typically comprise a blend of backgrounds in drug development, clinical research, market strategy, and finance, all contributing their expertise to guide the company through its growth and development stages.
What is the current price of Aclaris Therapeutics, Inc. - Common Stock?
The current price of Aclaris Therapeutics, Inc. - Common Stock is 1.490
When was Aclaris Therapeutics, Inc. - Common Stock last traded?
The last trade of Aclaris Therapeutics, Inc. - Common Stock was at 4:00 pm EDT on April 3rd, 2025
What is the market capitalization of Aclaris Therapeutics, Inc. - Common Stock?
The market capitalization of Aclaris Therapeutics, Inc. - Common Stock is 160.70M
How many shares of Aclaris Therapeutics, Inc. - Common Stock are outstanding?
Aclaris Therapeutics, Inc. - Common Stock has 107.85M shares outstanding.